NDC product
Sitagliptin and Metformin hydrochloride
NDC 10370-318 · Par Health USA, LLC
Key facts
| Product NDC | 10370-318 |
|---|---|
| Proprietary name | Sitagliptin and Metformin hydrochloride |
| Nonproprietary name | sitagliptin and metformin hydrochloride |
| Substances | SITAGLIPTIN PHOSPHATE, METFORMIN HYDROCHLORIDE |
| Dosage form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Par Health USA, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA204144 |
| Pharmacologic classes | Biguanide [EPC], Biguanides [CS], Dipeptidyl Peptidase 4 Inhibitor [EPC], Dipeptidyl Peptidase 4 Inhibitors [MoA] |
| Marketing start | Jul 24, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: